First filing for Astellas' SGLT2 inhibitor contender ipragliflozin, in Japan
This article was originally published in Scrip
Executive Summary
Astellas has landed the first blow in what will be a highly competitive market for sodium-glucose co-transporter 2 (SGLT2) inhibitors in Japan, with an approval filing for ipragliflozin (ASP1941) for type 2 diabetes.